Through its joint venture with Samsung Bioepis, Biogen Idec has exercised its right to enter an agreement to commercialize anti-TNF biosimilar product candidates in Europe, which include widely used therapies to treat rheumatoid arthritis and Crohn’s disease. The agreement with Samsung Bioepis is part of Biogen’s corporate objectives to remain focused on its core business, while leveraging its manufacturing expertise for biosimilar therapies.
“This is a unique opportunity for us to leverage our experience in developing and manufacturing high-quality biologics in therapeutic areas where we are deeply focused, and provide medicines to patients where there is a significant societal need,” said Tony Kingsley, executive vice president of global commercial operations for Biogen Idec. “As a company that aims to make a difference in the lives of patients with serious diseases, we are excited by the potential to offer additional highly effective therapies in critical areas where there is growing demand.”
“Biogen Idec has been an innovative joint venture partner in Samsung Bioepis and now with this agreement we are excited to extend our relationship into commercial operations,” said Christopher Hansung Ko, Ph.D., chief executive officer of Samsung Bioepis. “Samsung Bioepis has established a global commercialization plan for its antibody drugs currently under development, and we believe this agreement will further serve as a solid foundation for Samsung Bioepis to develop into a worldwide biosimilar leader.”